Completed
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
NCT06322342
- Conditions
- Acoustic Neuroma, Autoimmune Diseases, Autoimmune Diseases of the Nervous System, +61 more
- Locations
-
- Yale New Haven Hospital New Haven, Connecticut, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- Brigham & Women's Hospital Boston, Massachusetts, United States
- University of Missouri Columbia, Missouri, United States